CA2561210A1 — Novel 2-amino-imidazo[4,5-d]pyridazin-4-ones and 2-amino-imidazo[4,5-c]pyridin-4-ones, production and use thereof as medicaments
Assigned to Boehringer Ingelheim International GmbH · Expires 2005-10-20 · 21y expired
What this patent protects
The invention relates to 2-amino-imidazo[4,5-d]pyridazin-4-ones and 2-amino-imidazo[4,5-c]pyridin-4-ones of general formula (I), where R1 to R4 and X are as defined in claims 1 to 6, the tautomers, enantiomers, diastereomers, mixtures and salts thereof with useful pharmacological…
USPTO Abstract
The invention relates to 2-amino-imidazo[4,5-d]pyridazin-4-ones and 2-amino-imidazo[4,5-c]pyridin-4-ones of general formula (I), where R1 to R4 and X are as defined in claims 1 to 6, the tautomers, enantiomers, diastereomers, mixtures and salts thereof with useful pharmacological properties, in particular an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.